Compare GSK plc (GSK) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs UnitedHealth Group Inc — how do they compare? GSK plc trades at $51.53 (market cap $101.34B), while UnitedHealth Group Inc trades at $446.92 (market cap $380.08B). The key difference: UnitedHealth Group Inc is far larger — about 3.8× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | UNH | |
|---|---|---|
Market Cap | $101.34B | $380.08B |
Sector | Health | Health |
52-Week High | $61.18 | $431.68 |
52-Week Low | $36.20 | $237.77 |
Enterprise Value | $121.95B | $426.76B |
Dividend Yield | 3.49% | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
UnitedHealth Group (UNH) trades at $425.19, down 0.91% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growth to $447.57B in 2025 and consistent earnings beats, though net margins have compressed. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
Outlook remains positive with an 82.69% analyst buy rating and $438.33 consensus target, but risks include regulatory lawsuits and debt levels. The aging U.S. population and tech investments provide growth tailwinds, yet investors should monitor margin pressures and legal challenges from state Medicaid suits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
